ArticleJournal of cancer research and clinical oncology2025
Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Trends in male breast cancer in Spain, 1999-2023: a nationwide analysis of incidence and mortality.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Male Breast Cancer: Evaluating the Current Landscape of Diagnosis and Treatment.Breast cancer (Dove Medical Press) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the present study was to compare patient, tumor characteristics and prognostic factors as well as diagnostics and therapies between men and women with breast cancer. The rates of primary distant metastases, contralateral second tumors, overall survival (OS), recurrence, and recurrence-free survival (RFS) were analyzed and compared between men and women.
methodsThis retrospective cohort study included patient data from 18 clinical cancer registries in Germany (2000-2018). Differences in risk factors and short-term endpoints were analyzed via univariable and multivariable binary logistic regression analyses. OS, RFS, and the rate of subsequent second tumors were examined via Kaplan‒Meier, univariable and multivariable Cox regression methods.
resultsCompared with women, male patients with breast cancer presented a significantly greater risk of unfavorable prognostic factors, such as advanced stage, lymphatic invasion, and more primary distant metastases. While sentinel lymph node biopsy and HER-2 testing were comparable, treatment rates for men were 9.5-29.0% lower than those for women. In multivariable analyses, men had a 1.32-fold increased risk of death (95% CI 1.24-1.41; p < 0.001). The risk of recurrence/mortality was significantly increased by a factor of 1.531 (95% CI 1.43-1.65; p < 0.001). Adjustment for therapy in a multivariable regression model did not significantly affect the risk of death. Nevertheless, men had a survival benefit from systemic therapies comparable to that of women.
conclusionNeither patient and tumor characteristics nor differences in therapy could completely explain the difference in mortality between men and women. Differences in lifestyle or biological factors could play a role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.